Related Experiment Video

Updated: Jul 21, 2025

Lung microRNA Profiling Across the Estrous Cycle in Ozone-exposed Mice
07:07

Lung microRNA Profiling Across the Estrous Cycle in Ozone-exposed Mice

Published on: January 7, 2019

6.2K

miRNAs as Modern Biomarkers in Asthma Therapy

Natalia Kierbiedź-Guzik1, Barbara Sozańska2

  • 114th Paediatric Ward-Pulmonology and Allergology, J. Gromkowski Provincial Specialist Hospital, ul. Koszarowa 5, 51-149 Wrocław, Poland.

International Journal of Molecular Sciences
|July 29, 2023
PubMed

Insights

MicroRNAs (miRNAs) are small RNA molecules that regulate gene expression and play a role in asthma. This review highlights their potential in predicting asthma treatment effectiveness, diagnosing exacerbations, and assessing drug compliance.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Immunology

Background:

  • Asthma is a chronic airway inflammatory disease with symptoms like wheezing and coughing.
  • MicroRNAs (miRNAs) are small non-coding RNAs regulating gene expression post-transcriptionally.
  • miRNAs influence airway structure, cytokine production, and immune responses relevant to asthma.

Purpose of the Study:

  • To review the latest research on microRNAs (miRNAs) in asthma.
  • To explore the potential of miRNAs in asthma diagnosis, monitoring, and treatment.
  • To present miRNAs as predictive biomarkers for treatment efficacy and patient compliance.

Main Methods:

  • Literature review of recent studies on miRNAs and asthma.
  • Analysis of miRNA's role in gene expression regulation relevant to asthma pathogenesis.
  • Examination of evidence linking miRNA expression to asthma exacerbations and drug response.

Main Results:

  • miRNAs are implicated in key biological processes underlying asthma.
  • Evidence suggests miRNAs can predict treatment effectiveness in asthma patients.
  • miRNAs show potential for early diagnosis of asthma exacerbations and assessing drug compliance.

Conclusions:

  • MicroRNAs represent a promising area for asthma research and clinical application.
  • miRNAs can serve as valuable biomarkers for personalized asthma management.
  • Future therapeutic strategies may target miRNA pathways for novel asthma treatments.
Keywords:
antagomirasthmabeta-mimeticbiological therapybiomarkersglucocorticosteroidsinfectionmiRNApathwaysresponsetreatment

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.7K

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
346
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
446
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
340
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
361